目的 探讨银丹心脑通软胶囊联合注射用纤溶酶治疗脑梗死的临床疗效。方法 选取2013年10月-2015年6月天津市北辰医院收治的脑梗死患者80例，按照随机数字表法随机分为对照组和治疗组，每组各40例。对照组静脉滴注注射用纤溶酶，100 U加入到250 mL葡萄糖注射液中，滴注速度50滴/min，1次/d。治疗组在对照组基础上口服银丹心脑通软胶囊，3粒/次，3次/d。两组患者均连续治疗12 d。观察两组的临床疗效，比较两组美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数（BI）评分、血液流变学指标情况。结果 治疗后，对照组和治疗组的总有效率分别为67.5%、87.5%，两组比较差异有统计学意义（P<0.05）。治疗后，两组NIHSS评分均显著下降，BI评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组全血黏度、血浆黏度和血小板聚集率均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的下降程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 银丹心脑通软胶囊联合注射用纤溶酶治疗脑梗死具有较好的临床疗效，能改善神经功能，提高生活自理能力，改善血液流变学指标，具有一定的临床推广应用价值。

Objective To study the clinical effects of Yindan Xinnaotong Soft Capsules combined with Fibrinogenase for injection in treatment of cerebral infarction. Methods Patients (80 cases) with cerebral infarction in Tianjin Beichen Hospital from October 2013 to June 2015 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Fibrinogenase for injection, 100 U added into glucose solution 250 mL, 50 drops/min, once daily. Patients in the treatment group were po administered with B Yindan Xinnaotong Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores, BI scores, and blood rheology indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 67.5% and 87.5%, respectively, and there was difference between two groups (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, but BI scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, whole blood viscosity, plasma viscosity, and platelet aggregation rate in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Yindan Xinnaotong Soft Capsules combined with Fibrinogenase for injection has clinical curative effect in treatment of cerebral infarction, can improve nerve function, increase self-care ability, and Improve blood rheology index, which has a certain clinical application value.